Subject : Cross sectional survey to gather insights on the perception & usage of existing therapies in the management of Chronic Kidney Disease associated with Type 2 diabetes among Indian physicians
Chronic Kidney Disease is a progressive condition that affects >10% of the general population worldwide, amounting to >800 million individuals. Chronic Kidney Disease deaths have increased by 41.5% from 1990 to 2020, rising from the 17th leading cause of death to the 10th now. It is expected that CKD will climb to the fifth leading cause of death globally by the year 2040.
CKD is most commonly prevalent in individuals with diabetes & hypertension, women, elderly & racial minorities. Despite glycemic & BP treatments, >30% of patients with diabetes will develop CKD. Diabetes with early kidney involvement can shorten life expectancy by 16 years. One of the major challenges for management of CKD include screening & awareness. The ADA, KDIGO & ESC/EASD guidelines recommend screening for kidney dysfunction by laboratory evaluation of urinary albumin creatinine ratio & eGFR at least once a year in all patients with T2D regardless of treatment.
The existing therapies for management of CKD target the metabolic & hemodynamic factors, while establishing the need for newer therapies that target the inflammation & fibrosis pathway.
The ADA guidelines recommends a multifactorial approach to reduce the risk of diabetes complications targeting the reduction in diabetes complications such as glycemic management, blood pressure management, lipid management & agents with cardiovascular and kidney benefits.
We, at Sun Pharma, always strive to be abreast about the current clinical practices, and perceptions about existing treatment options. With this survey, we intend to understand the perception & the treatment options for the management of Chronic Kidney Disease with T2D.
The summary/outcome of the same will help us to better understand practice patterns, gap areas and enrich future learning needs, and to improve the care of CKD associated with T2D. Your responses will be used at an aggregate level.
|
}}){kind=logo}